Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
288
-
Total 13F shares, excl. options
-
90.1M
-
Shares change
-
-493K
-
Total reported value, excl. options
-
$2.02B
-
Value change
-
-$18.7M
-
Put/Call ratio
-
1.33
-
Number of buys
-
152
-
Number of sells
-
-121
-
Price
-
$22.38
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q2 2024
344 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 288 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 90.1M shares
of 108M outstanding shares and own 83.57% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (11.6M shares), BlackRock Inc. (9.6M shares), VANGUARD GROUP INC (9.1M shares), Deep Track Capital, LP (4.8M shares), STATE STREET CORP (4.36M shares), Sumitomo Mitsui Trust Holdings, Inc. (3.26M shares), Nikko Asset Management Americas, Inc. (3.26M shares), MORGAN STANLEY (2.34M shares), FEDERATED HERMES, INC. (2.3M shares), and GEODE CAPITAL MANAGEMENT, LLC (2.29M shares).
This table shows the top 288 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.